Quick viewing(Text Mode)

Supplementary Material

Supplementary Material

Supplementary material4.Utilizationpatternofantihypertensivedrugsamongnew(incident)users (prescriptions ofantihypertensivedrugsinthefirstsixweeksgestationwereexcluded) Supplementary material3.Utilizationpatternofantihypertensivedrugsamongprevalentusers:sensitivityanalysis Supplementary material2.Utilizationpatternofantihypertensivedrugsamongprevalentusers Supplementary material1.Definitionofcomorbiditiesandmedicationsinthepre-gestationalperiod This PDFfileincludes: DOI: 10.4415/ANN_15_03_12 Ann IstSuperSanità2015Vol. 51,No.3 Published on Email: [email protected] e PromozionedellaSalute,IstitutoSuperiorediSanità,Viale ReginaElena299,00161Rome,Italy. Carmen D’Amore,RepartodiFarmacoepidemiologia,CentroNazionaleEpidemiologia,Sorveglianza *Corresponding author: and GiuseppeTraversa Carmen D’Amore,FrancescoTrotta, RobertoDaCas,CarloZocchetti, AlfredoCocci : apopulationbasedstudy Antihypertensive druguseduring Supplementary Materialsfor www.iss.it/anna Ann IstSuperSanità2015|Vol. 51,No.3

Supplementary Materials Supplementary Materials b a period of andmedicationsDefinition comorbidities inthepre-gestational materialSupplementary 1 ICD 9 codes: International ClassificationofDiseases, IX ICD 9codes:International ATC codes: Anatomical Therapeutic Chemical(ATC) classificationsystem. Comorbidities andmedications Pulmonary/Respiratory Neurological andpsychiatric diseases malignancies) Hematological diseases(notincluding Digestive/intestinal antinflammatory Rare diseases Rare Immunodeficiencies Autoimmune diseases Thyroid diseases forAntibacterial systemic use supplementation Iron Folic ofpregnancy) firsttrimester acid(during Folic acid(before thepregnancy onset) NSAIDs for humanfertilization Oral contraceptives reflux disease gastro-oesophageal Drugs for pepticulcerand Antiepileptics Immunosuppressive drugs ICD 9 490-496 290-319; 330-359 250 280-289 555-558 th revision. a codes ATC codes R03 N04, N05,N06DA, N06DX A10 H03AA J01 B03AA; B03AB;B03AC; B03AE B03BB B03BB M01A;N02B L02AE G03G; G03D;H01AA;H01CC; G03A A02B N03A N06A L04A A07E b Disease allowanceDisease codes 007; 024 046 005; 011;014;017;029;038;044; 012; 013 027; 035 RLx; RMx;RNx RJx; RIx; RDx;RFx;RGx; RAx; RBx;RCx; 020; 048;050;052 037; 047;054;056 003; 006;009;028;030;034;036; b a in thefirstsix weeks ofgestation were excluded) Utilization pattern ofantihypertensive drugsamongprevalent analysis (prescriptions users:sensitivity ofantihypertensive drugs materialSupplementary 3 b a Utilization pattern ofantihypertensive drugsamongprevalent users materialSupplementary 2 Users may to contribute more thanonecategory. Users may to contribute more thanonecategory. The β-blockers category mainlyincludedatenolol, category andnebivolol.The β-blockers mainlyincludedatenolol, bisoprolol category andnebivolol.The b-blockers Calcium channelantagonists dihydropyridines b-blockers Total recommended drugs a-blockers anddiureticsb-blockers receptorImidazoline agonists Calcium channelantagonistsnondihydropyridines Combined aandbblockers , combinations Diuretics IIreceptor blockers, combinations Angiotensin IIreceptor blockers ACE inhibitors, associations ACE inhibitors Total non-recommended drugs Calcium channelantagonistsdihydropyridines b-blockers ACE inhibitors Total non-recommended drugs Methyldopa ACE inhibitors, associations Angiotensin IIreceptor blockers Angiotensin IIreceptor blockers, combinations Diuretics Diuretics, combinations Combined aandbblockers dihydropyridines Calcium channelantagonistsnon Imidazoline receptorImidazoline agonists -blockers anddiureticsb-blockers a-blockers Total recommended drugs b b a a a a 108 172 68 81 37 29 15 26 10 12 N 7 4 4 6 2 2 Trimester I (38.6) (61.4) (24.3) (28.9) (13.2) (10.4) (5.4) (9.3) (2.5) (3.6) (4.3) (1.4) (1.4) (2.1) (0.7) (0.7) (%) 131 45 23 92 48 N 9 1 1 4 1 2 5 3 2 Trimester - - II (74.4) (25.6) (13.1) (52.3) (27.3) (5.1) (0.6) (0.6) (2.3) (0.6) (1.1) (2.8) (1.7) (1.1) N =155 (%) - - 73 82 29 50 10 12 39 2 1 5 3 4 4 4 3 7 Trimester 137 I 49 25 88 61 N 7 3 2 3 2 2 4 5 Trimester - - - III (47.1) (52.9) (18.7) (32.3) (25.2) (%) (1.3) (0.6) (3.2) (1.9) (2.6) (2.6) (2.6) (1.9) (6.5) (4.5) (7.7) (73.7) (26.3) (13.4) (47.3) (32.8) (3.8) (1.6) (1.1) (1.6) (1.1) (1.1) (2.2) (2.7) (%) - - -

Supplementary Materials Supplementary Materials Utilization pattern of antihypertensive drugs among new (incident)users drugsamongnew ofantihypertensive pattern Utilization materialSupplementary 4 d c b a Data shown inthetablewere referred treatment ofpregnancy. ineachofthetrimesters to patientsstarting 6 women started treatment different withtwo 6 women started drugsinthethird antihypertensive trimester. 3 women started treatment different withtwo 3 women started trimester. drugsinthefirst antihypertensive -blockers category mainlyincludedatenolol, bisoprolol category andnebivolol.The β-blockers 4 women started treatment different withtwo 4 women started drugsinthesecondtrimester. antihypertensive ACE inhibitors Total non-recommended drugs ACE inhibitors, associations b-blockers Angiotensin IIreceptor blockers combinations Angiotensin IIreceptor blockers, Diuretics Diuretics, combinations Combined aandbblockers dihydropyridines Calcium channelantagonistsnon Imidazoline receptorImidazoline agonists -blockers anddiureticsb-blockers a-blockers Other substances Other Total recommended drugs dihydropyridines Calcium channelantagonists Methyldopa d 87 48 24 11 11 10 46 N 6 8 7 4 3 1 1 1 1 4 Trimester I (64.4) (35.6) a (17.8) (34.1) (8.1) (8.1) (7.4) (4.4) (5.9) (5.2) (2.9) (2.2) (0.7) (0.7) (0.7) (0.7) (2.9) (%) 102 58 13 10 89 18 N 6 9 5 3 2 4 2 2 1 - - Trimester II b (36.3) (63.7) (55.6) (11.2) (8.1) (6.3) (3.8) (5.6) (3.1) (1.9) (1.3) (2.5) (1.3) (1.3) (0.6) (%) - - 314 285 66 17 14 33 N 7 2 8 8 5 3 1 2 2 1 - Trimester III (17.4) (82.6) (75.0) c (4.5) (3.7) (1.8) (0.5) (2.1) (2.1) (1.3) (0.8) (0.3) (0.5) (0.5) (0.3) (8.7) (%) -

Top View